Peripartum depression: current considerations on classification, biological importance, and therapeutic potential of neuroactive steroids
References
1. Biaggi A, Conroy S, Pawlby S, Pariante CM. Identifying the women at risk of antenatal anxiety and depression: A systematic review. J Affect Disord 2016; 191: 62–77.
2. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005; 106(5 Pt 1): 1071–83.
3. Dmitrovic BK, Dugalić MG, Balkoski GN, Dmitrovic A, Soldatovic I. Frequency of perinatal depression in Serbia and associated risk factors. Int J Soc Psychiatry 2014; 60(6): 528–32.
4. Stojanov J, Stojanov A, Stanković M. Risk factors for postpartum depression in the early postpartum period. Praxis Medica 2019; 48(2): 33‒37 (Serbian)
5. Chaudron LH, Szilagyi PG, Tang W, Anson E, Talbot NL, Wadkins HIM, et al. Accuracy of Depression Screening Tools for Identifying Postpartum Depression Among Urban Mothers. Pediatrics 2010; 125(3): e609–17.
6. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health 2005; 8(2): 77–87.
7. Mauri M, Oppo A, Borri C, Banti S. PND-ReScU group. SUICIDALITY in the perinatal period: comparison of two self-report instruments. Results from PND-ReScU. Arch Womens Ment Health 2012; 15(1): 39–47.
8. Admon LK, Dalton VK, Kolenic GE, Ettner SL, Tilea A, Haffajee RL, et al. Trends in Suicidality 1 Year Before and After Birth Among Commercially Insured Childbearing Individuals in the United States, 2006-2017. JAMA Psychiatry 2021; 78(2): 171–6.
9. Netsi E, Pearson RM, Murray L, Cooper P, Craske MG, Stein A. Association of Persistent and Severe Postnatal Depression With Child Outcomes. JAMA Psychiatry 2018; 75(3): 247–53.
10. World Health Organization. The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines [Internet]. World Health Organization; 1992 [cited 2022 Jan 31]. Available from: https://apps.who.int/iris
/>/handle/10665/37958
11. Ministry of Health of the Republic of Serbia. National guidelines for diagnosis and treatment of depression, 2012. Belgrade: Ministry of Health of the Republic of Serbia; 2012 (Serbian)
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013.
13. Yonkers KA, Ramin SM, Rush AJ, Navarrete CA, Carmody T, March D, et al. Onset and persistence of postpartum depression in an inner-city maternal health clinic system. Am J Psychiatry 2001; 158(11): 1856–63.
14. Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium. Heterogeneity of postpartum depression: a latent class analysis. Lancet Psychiatry 2015; 2(1): 59–67.
15. World Health Organization. International statistical classification of diseases and related health problems. (11th Revision). [Internet]. World Health Organization 2019; [cited 2022 Jan 31]. Retrieved from: https://icd.who.int/browse11/l-m/en
16. Wikman A, Axfors C, Iliadis SI, Cox J, Fransson E, Skalkidou A. Characteristics of women with different perinatal depression trajectories. J Neurosci Res 2020; 98(7): 1268–82.
17. Banti S, Mauri M, Oppo A, Borri C, Rambelli C, Ramacciotti D, et al. From the third month of pregnancy to 1 year postpartum. Prevalence, incidence, recurrence, and new onset of depression. Results from the perinatal depression-research & screening unit study. Compr Psychiatry 2011; 52(4): 343–51.
18. Stowe ZN, Hostetter AL, Newport DJ. The onset of postpartum depression: Implications for clinical screening in obstetrical and primary care. Am J Obstet Gynecol 2005; 192(2): 522–6.
19. O’Hara MW, Swain AM. Rates and risk of postpartum depression – a meta-analysis. Int Rev Psychiatry 1996; 8(1):37–54.
20. Vuković O, Damjanović A, Marić NP, Cvetić T, Zebić M, Britvić D, et al. Perinatal psychiatry: Guidelines in clinical practice. Engrami 2008; 30(3–4): 47–52.
21. Cox JL, Murray D, Chapman G. A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry 1993; 163: 27–31.
22. Myers ER, Aubuchon-Endsley N, Bastian LA, Gierisch JM, Kemper AR, Swamy GK, et al. Efficacy and Safety of Screening for Postpartum Depression [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 [cited 2022 Jan 28]. (AHRQ Comparative Effectiveness Reviews). Available from: http://www.ncbi.nlm.nih.gov/books/NBK137724/
23. Kozhimannil KB, Adams AS, Soumerai SB, Busch AB, Huskamp HA. New Jersey’s efforts to improve postpartum depression care did not change treatment patterns for women on medicaid. Health Aff (Millwood) 2011; 30(2): 293–301.
24. Avalos LA, Raine-Bennett T, Chen H, Adams AS, Flanagan T. Improved Perinatal Depression Screening, Treatment, and Outcomes With a Universal Obstetric Program. Obstet Gynecol 2016; 127(5): 917–25.
25. Putnam KT, Wilcox M, Robertson-Blackmore E, Sharkey K, Bergink V, Munk-Olsen T, et al. Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Lancet Psychiatry 2017; 4(6): 477–85.
26. Dickens M, Pawluski J. The HPA Axis During the Perinatal Period: Implications for Perinatal Depression. Endocrinology [Internet]. 2018 Nov 1 [cited 2022 Feb 3]; 159(11). Available from: https://pubmed.ncbi.nlm.nih.gov/30256957/
27. Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry 2003; 44(3): 234–46.
28. Hewitt SA, Wamsteeker JI, Kurz EU, Bains JS. Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis. Nat Neurosci 2009; 12(4): 438–43.
29. Melón LC, Hooper A, Yang X, Moss SJ, Maguire J. Inability to suppress the stress-induced activation of the HPA axis during the peripartum period engenders deficits in postpartum behaviors in mice. Psychoneuroendocrinology 2018; 90: 182–93.
30. Deligiannidis KM, Fales CL, Kroll-Desrosiers AR, Shaffer SA, Villamarin V, Tan Y, et al. Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance imaging and spectroscopy study. Neuropsychopharmacology 2019; 44(3): 546–54.
31. Maguire J, Mody I. Behavioral Deficits in Juveniles Mediated by Maternal Stress Hormones in Mice. Neural Plast 2016; 2016: 2762518.
32. Deligiannidis KM, Kroll-Desrosiers AR, Mo S, Nguyen HP, Svenson A, Jaitly N, et al. Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for depression. Psychoneuroendocrinology 2016; 70: 98–107.
33. Schüle C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog Neurobiol 2014; 113: 79–87.
34. Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron 2008; 59(2): 207–13.
35. Licheri V, Talani G, Gorule AA, Mostallino MC, Biggio G, Sanna E. Plasticity of GABAA Receptors during Pregnancy and Postpartum Period: From Gene to Function. Neural Plast 2015; 2015: 170435.
36. Gilbert Evans SE, Ross LE, Sellers EM, Purdy RH, Romach MK. 3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. Gynecol Endocrinol 2005; 21(5): 268–79.
37. Klak J, Hill M, Parízek A, Havlíková H, Bicikova M, Hampl R, et al. Pregnanolone isomers, pregnenolone and their polar conjugates around parturition. Physiol Res 2003; 52: 211–21.
38. Luisi S, Petraglia F, Benedetto C, Nappi RE, Bernardi F, Fadalti M, et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab 2000; 85(7): 2429–33.
39. Nappi RE, Petraglia F, Luisi S, Polatti F, Farina C, Genazzani AR. Serum allopregnanolone in women with postpartum “blues.” Obstet Gynecol 2001; 97(1): 77–80.
40. Roomruangwong C, Anderson G, Berk M, Stoyanov D, Carvalho AF, Maes M. A neuro-immune, neuro-oxidative and neuro-nitrosative model of prenatal and postpartum depression. Prog Neuropsychopharmacol Biol Psychiatry 2018; 81: 262–74.
41. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol 2001; 16(1): 95–103.
42. Cassidy-Bushrow AE, Peters RM, Johnson DA, Templin TN. Association of depressive symptoms with inflammatory biomarkers among pregnant African-American women. J Reprod Immunol 2012; 94(2): 202–9.
43. Boufidou F, Lambrinoudaki I, Argeitis J, Zervas IM, Pliatsika P, Leonardou AA, et al. CSF and plasma cytokines at delivery and postpartum mood disturbances. J Affect Disord 2009; 115(1–2): 287–92.
44. Achtyes E, Keaton SA, Smart L, Burmeister AR, Heilman PL, Krzyzanowski S, et al. Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression. Brain Behav Immun 2020; 83: 239–47.
45. Kudo Y, Hara T, Katsuki T, Toyofuku A, Katsura Y, Takikawa O, et al. Mechanisms regulating the expression of indoleamine 2,3‐dioxygenase during decidualization of human endometrium. Hum Reprod 2004; 19(5): 1222–30.
46. Badawy AA. Effects of pregnancy on tryptophan metabolism and disposition in the rat. Biochem J 1988; 255(1): 369–72.
47. Keaton SA, Heilman P, Bryleva EY, Madaj Z, Krzyzanowski S, Grit J, et al. Altered Tryptophan Catabolism in Placentas From Women With Pre-eclampsia. Int. J. Tryptophan Res. [Internet]. 2019 Apr 1 [cited 2022 Feb 4];12. Available from: http://www.scopus.com/inward/record.url?scp=85069612092&partnerID=8YFLogxK>
48. Frieder A, Fersh M, Hainline R, Deligiannidis KM. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. CNS Drugs 2019; 33(3): 265–82.
49. Milovanovic S, Djuric D, Damjanovic A. Depression – risk factors in women. In: Ilić K, Tasić Lj, editors. Women’s health in Serbia - Health Promotion, Disease Prevention and Therapy. Belgrade: University of Belgrade, Faculty of Pharmacy; 2009. p. 329‒35. (Serbian)
50. Molyneaux E, Telesia LA, Henshaw C, Boath E, Bradley E, Howard LM. Antidepressants for preventing postnatal depression. Cochrane Database Syst Rev 2018; 2018(4): CD004363.
51. Pirec V. Current dilemmas in treating the depressed pregnant patients. Engrami 2011; 33(2): 51–62.
52. Milovanovic S, Latas M. Desvenlafaxine extended release. Belgrade: CEDUP; 2021. (Serbian)
53. U.S. Food and Drug Administration. FDA approves first treatment for post-partum depression [Internet]. FDA; 2020 [cited 2022 Feb 4]. Available from: https://www.fda.
/>gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression
54. Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 2017; 390(10093): 480–9.
55. Kanes SJ, Colquhoun H, Doherty J, Raines S, Hoffmann E, Rubinow DR, et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol 2017; 32(2): e2576.
56. Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 2018 Sep 22; 392(10152): 1058–70.
57. Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics Inc. U.S. Food and Drug Administration website; [Internet] 2019 [cited 2022 Feb 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label
/>/2019/211371lbl.pdf
58. Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry 2021; 78(9): 951–9.